Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


23.12.2018

1 Anticancer Res
2 BJU Int
2 BMC Cancer
1 Br J Radiol
3 Cancer
6 Eur Urol
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Cell Physiol
1 J Magn Reson Imaging
3 J Nucl Med
1 J Urol
1 JAMA
1 Oncogene
3 PLoS One
2 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. GIACINTI S, Poti G, Roberto M, Macrini S, et al
    Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
    Anticancer Res. 2018;38:6029-6039.
    PubMed     Text format     Abstract available


    BJU Int

  2. GUPTA N, Bivalacqua TJ, Han M, Gorin MA, et al
    Evaluating the Impact of Length of Time from Diagnosis to Surgery in Patients with Unfavorable Intermediate to Very High-Risk Clinically Localized Prostate Cancer.
    BJU Int. 2018 Dec 20. doi: 10.1111/bju.14659.
    PubMed     Text format     Abstract available

  3. OMLIN A, Gillessen S
    The Advanced Prostate Cancer Consensus on a regional level - what can we learn?
    BJU Int. 2019;123:3-4.
    PubMed     Text format    


    BMC Cancer

  4. BOSSAN A, Ottman R, Andl T, Hasan MF, et al
    Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.
    BMC Cancer. 2018;18:1257.
    PubMed     Text format     Abstract available

  5. CULTRARA CN, Kozuch SD, Ramasundaram P, Heller CJ, et al
    GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.
    BMC Cancer. 2018;18:1263.
    PubMed     Text format     Abstract available


    Br J Radiol

  6. NANDURKAR R, van Leeuwen P, Stricker P, Woo H, et al
    (68)Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
    Br J Radiol. 2018 Dec 19:20180667. doi: 10.1259/bjr.20180667.
    PubMed     Text format     Abstract available


    Cancer

  7. WHITE C, Nimeh T, Gazelle GS, Weinstein MC, et al
    A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31884.
    PubMed     Text format     Abstract available

  8. KING MT, Nguyen PL, D'Amico AV, Orio PF 3rd, et al
    Reply to Partial gland therapy for prostate cancer.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31822.
    PubMed     Text format    

  9. HOGE C, George A, Sidana A
    Partial gland therapy for prostate cancer.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31823.
    PubMed     Text format    


    Eur Urol

  10. PADHANI AR, Haider MA, Villers A, Barentsz JO, et al
    Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)30963.
    PubMed     Text format    

  11. HAMID AA, Gray KP, Shaw G, MacConaill LE, et al
    Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30949.
    PubMed     Text format     Abstract available

  12. DAL PRA A, Abramowitz M, Pollack A
    Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30958.
    PubMed     Text format    

  13. YANG DD, Mahal BA, Muralidhar V, Martin NE, et al
    Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Eur Urol. 2019;75:35-41.
    PubMed     Text format     Abstract available

  14. GOKCE A, Gul D
    Re: Mark Douglas Tyson II, Tatsuki Koyama, Dan Lee, et al. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol 2018;74:26-33.
    Eur Urol. 2018 Dec 14. pii: S0302-2838(18)31000.
    PubMed     Text format    

  15. WEI Y, Li T, Liu L
    Re: Alberto Briganti, Nicola Fossati, James W.F. Catto, et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:357-68.
    Eur Urol. 2018 Dec 15. pii: S0302-2838(18)31001.
    PubMed     Text format    


    Int J Cancer

  16. GAO X, Wilsgaard T, Jansen EH, Holleczek B, et al
    Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32073.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. ZUMSTEG ZS, Spratt DE
    Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?
    Int J Radiat Oncol Biol Phys. 2019;103:92-94.
    PubMed     Text format    

  18. VAUGIER L, Palpacuer C, Rio E, Goineau A, et al
    Early toxicity of a phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07).
    Int J Radiat Oncol Biol Phys. 2018 Dec 14. pii: S0360-3016(18)34186.
    PubMed     Text format     Abstract available


    J Cell Physiol

  19. ZHANG G, He X, Ren C, Lin J, et al
    Long noncoding RNA PCA3 regulates prostate cancer through sponging miR-218-5p and modulating high mobility group box 1.
    J Cell Physiol. 2018 Dec 19. doi: 10.1002/jcp.27980.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  20. DEVINE W, Giganti F, Johnston EW, Sidhu HS, et al
    Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T2 MR Images.
    J Magn Reson Imaging. 2018 Dec 19. doi: 10.1002/jmri.26608.
    PubMed     Text format     Abstract available


    J Nucl Med

  21. SCHMIDT-HEGEMANN NS, Chukwuka E, Minglun L, Rogowski P, et al
    Impact of (68)Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate cancer in comparison to CT - a retrospective analysis.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.220855. doi: 10.2967/jnumed.118.220855.
    PubMed     Text format     Abstract available

  22. CHEN M, Zhang Q, Zhang C, Zhao X, et al
    Combination of (68)Ga-PSMA PET/CT and multiparameter MRI improves the detection of clinically significant prostate cancer: a lesion by lesion analysis.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.221010. doi: 10.2967/jnumed.118.221010.
    PubMed     Text format     Abstract available

  23. EMMETT LM, Yin C, Crumbaker M, Hruby G, et al
    Rapid modulation of PSMA expression by Androgen deprivation: Serial (68)Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.223099. doi: 10.2967/jnumed.118.223099.
    PubMed     Text format     Abstract available


    J Urol

  24. BEKSAC AT, Cumarasamy S, Falagario U, Xu P, et al
    Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    J Urol. 2018;200:1241-1249.
    PubMed     Text format     Abstract available


    JAMA

  25. MAHAL BA, Berman RA, Taplin ME, Huang FW, et al
    Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men.
    JAMA. 2018;320:2479-2481.
    PubMed     Text format    


    Oncogene

  26. XIE Y, Fan H, Lu W, Yang Q, et al
    Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0608.
    PubMed     Text format     Abstract available


    PLoS One

  27. TINZL M, Chen B, Chen SY, Semenas J, et al
    Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
    PLoS One. 2018;13:e0209544.
    PubMed     Text format     Abstract available

  28. HUANG MH, Blackwood J, Godoshian M, Pfalzer L, et al
    Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
    PLoS One. 2018;13:e0208573.
    PubMed     Text format     Abstract available

  29. PARK JW, Lee JH, Cho HJ, Ha YJ, et al
    Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study.
    PLoS One. 2018;13:e0209049.
    PubMed     Text format     Abstract available


    Prostate

  30. JOHNG D, Torga G, Ewing CM, Jin K, et al
    HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Prostate. 2018 Dec 17. doi: 10.1002/pros.23747.
    PubMed     Text format     Abstract available

  31. IWAMOTO H, Izumi K, Natsagdorj A, Naito R, et al
    Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells.
    Prostate. 2018 Dec 19. doi: 10.1002/pros.23753.
    PubMed     Text format     Abstract available


    Urology

  32. BRASSETTI A, D'Elia G
    Reply by the Authors.
    Urology. 2018;115:189.
    PubMed     Text format    

  33. MARTIN DT, Ghabili K, Levi A, Humphrey PA, et al
    Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than PI-RADS Score in Multi-Parametric Prostate MRI-Ultrasound Fusion Targeted Biopsies.
    Urology. 2018 Dec 12. pii: S0090-4295(18)31306.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: